Consistent with this assumption, B cell depletion by rituximab in MS patients led to a drop in CXCL9 production (Figure 4H) and thus provides an additional explanation why T cell activation and AP are reduced by anti-CD20 treatment.3 The gene discussed is CXCL9; the disease is myeloid sarcoma.